90272-83-6

Basic information

• Product Name: 4-CHLORO-7-METHYL-QUINAZOLINE
• Synonyms: 4-CHLORO-7-METHYL-QUINAZOLINE;Quinazoline, 4-chloro-7-methyl-
• CAS NO: 90272-83-6
• Molecular Formula: C₉H₇ClN₂
• Molecular Weight: 178.621
• Product Categories: Quinoline series
• Mol File: 90272-83-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 298.166°C at 760 mmHg
• Flash Point: 162.308°C
• Appearance: /
• Density: 1.292g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.643
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-CHLORO-7-METHYL-QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-7-METHYL-QUINAZOLINE(90272-83-6)
• EPA Substance Registry System: 4-CHLORO-7-METHYL-QUINAZOLINE(90272-83-6)

Safety Data

• Hazardous Substances Data: 90272-83-6(Hazardous Substances Data)

Usage

General Description

4-CHLORO-7-METHYL-QUINAZOLINE is a chemical compound with the molecular formula C9H7ClN2. It is a quinazoline derivative, which is a class of heterocyclic organic compounds. 4-CHLORO-7-METHYL-QUINAZOLINE is commonly used as a building block in medicinal chemistry research for the synthesis of various pharmaceutical drugs and agrochemicals. Additionally, it has shown potential biological activities, including anti-cancer and anti-inflammatory properties. The synthesis and study of 4-CHLORO-7-METHYL-QUINAZOLINE and its derivatives have garnered interest in the scientific community for their potential therapeutic applications.

InChI:InChI=1/C9H7ClN2/c1-6-2-3-7-8(4-6)11-5-12-9(7)10/h2-5H,1H3

Upstream product

• 2305-36-4 4-methylanthranilic acid 
• 75844-40-5 7-methyl-quinazolin-4(3H)-one 

Downstream Products

• 234098-35-2 7-Bromomethyl-4-chloroquinazoline 

Relevant articles and documents

Design, Synthesis and Bioevaluation of Two Series of 3-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-ones and N-(1-Benzylpiperidin-4-yl)quinazolin-4-amines

Two series of 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-ones and N-(1-benzylpiperidin-4-yl)quinazolin-4-amines were designed initially as potential acetylcholine esterase inhibitors. Biological evaluation demonstrated that N-(1-benzylpiperidin-4-yl)quinazolin-4-amines significantly inhibited AChE activity. Especially, two compounds of them were found to be the most potent with relative AChE inhibition percentages of 87 percent in comparison to donepezil. The docking studies with AChE showed similar interactions between donepezil and four derivatives. N-(1-Benzylpiperidin-4-yl)quinazolin-4-amines also exhibited significant DPPH scavenging effects. The two series of compound also exerted moderate to good cytotoxicity against three human cancer cell lines, including SW620 (human colon cancer), PC-3 (prostate cancer), and NCI?H23 (lung cancer), with 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-one being the most cytotoxic agent. 3-[(1-Benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-one significantly induced early apoptosis and arrested the SW620 cells at G2/M phase. From this study, two compounds of N-(1-benzylpiperidin-4-yl)quinazolin-4-amines could serve as new leads for further design and AChE inhibitors, while 3-[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]quinazolin-4(3H)-one could serve as a new lead for the design and development of more potent anticancer agents.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Substituted oxoazaheterocyclyl compounds

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa..